Endo Pharmaceuticals Inc. offers SUPPRELIN® LA, an implanted gonadotropin releasing hormone (GnRH) medicine specifically for treating children with central precocious puberty (CPP). If your child is experiencing early puberty signs, such as light vaginal bleeding or breast enlargement in girls, SUPPRELIN® LA can help halt the progression.

The implant lasts for 12 months, providing continuous treatment. The insertion process is minimally invasive and requires a short recovery time before your child can resume normal activities. Regular doctor visits are essential for monitoring progress, with blood tests and exams to ensure the efficacy of the treatment.

Common side effects may include skin reactions at the implant site, which should be reported to the doctor. For comprehensive safety information and guidance, consult the full prescribing information. Take the first step to address CPP and support your child's health with SUPPRELIN® LA from Endo Pharmaceuticals Inc